Morgan Stanley’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,378
| Closed | -$72K | – | 7243 |
|
|
2020
Q3 | $72K | Sell |
1,378
-1,472
| -52% | -$90.8K | ﹤0.01% | 5576 |
|
|
2020
Q2 | $174K | Sell |
2,850
-2,920
| -51% | -$169K | ﹤0.01% | 5139 |
|
|
2020
Q1 | $326K | Sell |
5,770
-2,598
| -31% | -$148K | ﹤0.01% | 4617 |
|
|
2019
Q4 | $477K | Buy |
8,368
+6,055
| +262% | +$321K | ﹤0.01% | 4953 |
|
|
2019
Q3 | $123K | Buy |
2,313
+1,638
| +243% | +$95.4K | ﹤0.01% | 5365 |
|
|
2019
Q2 | $40K | Sell |
675
-15,656
| -96% | -$985K | ﹤0.01% | 5705 |
|
|
2019
Q1 | $1.02M | Buy |
16,331
+6,358
| +64% | +$421K | ﹤0.01% | 4101 |
|
|
2018
Q4 | $605K | Sell |
9,973
-18,914
| -65% | -$1.13M | ﹤0.01% | 4662 |
|
|
2018
Q3 | $1.69M | Buy |
28,887
+4,423
| +18% | +$226K | ﹤0.01% | 4144 |
|
|
2018
Q2 | $1.1M | Sell |
24,464
-2,291
| -9% | -$98.5K | ﹤0.01% | 4568 |
|
|
2018
Q1 | $1.19M | Sell |
26,755
-1,806
| -6% | -$75.9K | ﹤0.01% | 4424 |
|
|
2017
Q4 | $1.24M | Buy |
28,561
+7,571
| +36% | +$340K | ﹤0.01% | 4401 |
|
|
2017
Q3 | $977K | Sell |
20,990
-1,099
| -5% | -$52.6K | ﹤0.01% | 4446 |
|
|
2017
Q2 | $1.09M | Buy |
22,089
+11,246
| +104% | +$589K | ﹤0.01% | 4308 |
|
|
2017
Q1 | $594K | Sell |
10,843
-7,748
| -42% | -$410K | ﹤0.01% | 4734 |
|
|
2016
Q4 | $1.03M | Buy |
18,591
+16,403
| +750% | +$788K | ﹤0.01% | 4436 |
|
|
2016
Q3 | $101K | Buy |
2,188
+1,985
| +978% | +$79.7K | ﹤0.01% | 5309 |
|
|
2016
Q2 | $8K | Sell |
203
-5,655
| -97% | -$207K | ﹤0.01% | 6119 |
|
|
2016
Q1 | $204K | Sell |
5,858
-2,865
| -33% | -$105K | ﹤0.01% | 4965 |
|
|
2015
Q4 | $374K | Sell |
8,723
-35,552
| -80% | -$1.78M | ﹤0.01% | 4736 |
|
|
2015
Q3 | $1.93M | Buy |
44,275
+5,393
| +14% | +$291K | ﹤0.01% | 3549 |
|
|
2015
Q2 | $2.01M | Buy |
38,882
+2,785
| +8% | +$119K | ﹤0.01% | 3623 |
|
|
2015
Q1 | $1.41M | Sell |
36,097
-37,497
| -51% | -$1.47M | ﹤0.01% | 3870 |
|
|
2014
Q4 | $2.84M | Buy |
73,594
+13,388
| +22% | +$511K | ﹤0.01% | 3249 |
|
|
2014
Q3 | $2.13M | Buy |
60,206
+19,720
| +49% | +$579K | ﹤0.01% | 3387 |
|
|
2014
Q2 | $1.09M | Buy |
40,486
+33,259
| +460% | +$866K | ﹤0.01% | 3985 |
|
|
2014
Q1 | $187K | Buy |
7,227
+727
| +11% | +$17.4K | ﹤0.01% | 5150 |
|
|
2013
Q4 | $141K | Sell |
6,500
-6,172
| -49% | -$126K | ﹤0.01% | 5202 |
|
|
2013
Q3 | $247K | Sell |
12,672
-3,702
| -23% | -$65.6K | ﹤0.01% | 4758 |
|
|
2013
Q2 | $255K | Buy |
+16,374
| New | +$263K | ﹤0.01% | 4697 |
|
Other funds holding BSTC
Morgan Stanley's BSTC Position: Q4 2020 in Review
Morgan Stanley sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 1,378 shares — an estimated $72K sold.
Morgan Stanley first reported a position in BSTC in Q2 2013 and held it in 30 quarters. The position peaked at $2.84M in Q4 2014. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Morgan Stanley reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 1,378 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $72K.
- Morgan Stanley first reported a position in BioSpecifics Technologies Corp. in Q2 2013 and held it in 30 quarters.
- Morgan Stanley's BioSpecifics Technologies Corp. position peaked at $2.84M in Q4 2014.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.